Northwestern Mutual Wealth Management Co. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Northwestern Mutual Wealth Management Co. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,101 shares of the biopharmaceutical company’s stock after purchasing an additional 1,048 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Regeneron Pharmaceuticals were worth $3,180,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of REGN. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Dodge & Cox grew its holdings in Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after purchasing an additional 45,513 shares during the last quarter. Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after purchasing an additional 106,861 shares during the last quarter. Nuveen LLC increased its position in shares of Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported that a Phase 1/2 study combining cemiplimab with SNS-101 has reached completion. The update provides a development milestone, although no efficacy or regulatory data were disclosed, limiting its immediate impact. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: Industry research projects substantial growth in the global complement-inhibitor market through 2035 and lists Regeneron among the leading companies. The report supports the company’s long-term opportunity but does not provide a new company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Negative Sentiment: Multiple law firms announced or promoted securities class actions involving investors who purchased REGN shares between August 1, 2025, and May 15, 2026. The lawsuits allege that Regeneron and certain executives misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol change and eventual failure to meet its primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The legal claims may increase reputational, litigation, and potential financial risks, although the allegations have not been proven. Hagens Berman Regeneron Securities Fraud Class Action Alert Robbins Geller Regeneron Investor Alert
• Negative Sentiment: Director Kathryn Guarini and EVP Marion McCourt reported sales totaling roughly $2.34 million. All transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as discretionary bearish signals, but the sales can still weigh on sentiment near the stock’s recent highs. SEC insider transaction filing

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. HSBC lowered their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Truist Financial increased their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $800.36.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock worth $3,432,488 in the last 90 days. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $843.47 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a 50-day moving average of $734.39 and a two-hundred day moving average of $719.34. The stock has a market cap of $86.84 billion, a P/E ratio of 20.85, a P/E/G ratio of 1.67 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the prior year, the company earned $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.